# Hemovent

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hemovent

- Industry: Medical Devices & Equipment
- Headquarters: Aachen, Germany
- Website: www.hemovent.com
- Total disclosed funding: $19M
- Latest round: Series B (Oct 19, 2020)
- Investors on record: 9

## About

Hemovent GmbH is a German company focused on developing advanced medical devices that enhance patient care in critical healthcare environments, particularly through innovative respiratory support technologies.Founded in 2013 and headquartered in Aachen, Germany, Hemovent GmbH specializes in the design of medical devices for respiratory support. The company has received a total of EUR 5.50 mn across various funding rounds, with the most recent being an Add-on Trade Sale in October 2021, where Microport Scientific Corporation acquired Hemovent for EUR 123 mn. The CEO, Christof Lenz, leads the firm alongside Juergen Boehm.Hemovent specializes in advanced medical devices designed to optimize patient care in critical settings, focusing primarily on respiratory support and monitoring. The company’s flagship offerings include innovative ventilators and extracorporeal membrane oxygenation (ECMO) systems, engineered to assist patients with severe respiratory failure. These devices are utilized in hospitals and intensive care units, providing vital support for patients requiring assistance with breathing or circulatory support, particularly relevant in healthcare facilities across Europe and North America.Hemovent generates revenue primarily through direct sales of its medical equipment to healthcare institutions, operating within a B2B model. The company establishes partnerships with hospitals and clinics, facilitating significant transactions involving the procurement of high-value medical devices. Their revenue structure is supported by ongoing service agreements for maintenance and support, reflecting their commitment to long-term relationships with clients in critical care solutions.In the wake of the acquisition by Microport Scientific Corporation in October 2021, Hemovent plans to leverage its resources to enhance emergency and critical care solutions by integrating Cardiopulmonary Bypass (CPB) with the research and development of ECMO products. The company intends to explore new product developments aimed at improving patient outcomes, particularly in critical care environments. Additionally, there are plans for geographic expansion into Asian markets by 2023, utilizing the recent funding to support these initiatives and enhance the overall product offering.

## Funding rounds

- Series B, Oct 19, 2020, $5.5M — NRW Bank, MIG Capital, Seed Capital Partners
- Series B, Feb 4, 2019, $5.2M — KfW Banking Group, NRW Bank, MIG Capital, Seedfonds Aachen, First Capital Partner
- Series A, Jul 20, 2017, $2.3M — NRW Bank, MIG Capital, Seedfonds Aachen, KfW Mittelstandsbank, First Capital Partner
- Series A, Feb 10, 2016, $6M — KfW Banking Group, NRW Bank, MIG Capital, Wallstreet Commerce & Trade Institute, Inc., Seedfonds Aachen, PB Beteiligung - und Vermoegensverwaltung

## Investors

- KfW Banking Group — Series A, Series B
- NRW Bank — Series A, Series B
- MIG Capital (https://capitalatlas.ai/funds/mig-capital) — Series A, Series B
- Wallstreet Commerce & Trade Institute, Inc. — Series A
- Seedfonds Aachen — Series A, Series B
- PB Beteiligung - und Vermoegensverwaltung — Series A
- KfW Mittelstandsbank (https://capitalatlas.ai/funds/kfw-mittelstandsbank) — Series A
- First Capital Partner (https://capitalatlas.ai/funds/first-capital-partner) — Series A, Series B
- Seed Capital Partners (https://capitalatlas.ai/funds/seed-capital-partners) — Series B